The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain.

Within patient consistency of response, freedom from all migraine pain and symptoms, satisfaction, presence or absence of neck pain/discomfort, sinus pain/pressure, recurrence of head pain, safety and tolerability [ Time Frame: 2 to 24 hours ] [ Designated as safety issue: No ]

History of epilepsy or treated with anti-epileptics within past 5 years.

Impaired hepatic or renal function.

History of gastrointestinal bleeding or ulceration.

Allergy or hypersensitivity to Aspirin or any other NSAID.

Allergy or hypersensitivity to triptans.

Participated in an investigational drug trial in the previous 4 weeks.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00240630